Forbion Announces Closing of Initial Public Offering of Portfolio Company uniQure

  Forbion Announces Closing of Initial Public Offering of Portfolio Company

     From early investment to exit, uniQure exemplifies Forbion model for
     identifying world-leading research and active management involvement

Business Wire

NAARDEN, The Netherlands -- February 13, 2014

Forbion Capital Partners, the leading Dutch VC firm investing in world-class
healthcare technologies, is proud to announce that its portfolio company
uniQure N.V. (uniQure or the company) has closed its initial public offering
of ordinary shares at an initial public offering price of $17.00 per ordinary
share. uniQure's ordinary shares are listed on the NASDAQ Global Select Market
and began trading under the symbol "QURE" on February 5, 2014. Jefferies LLC
and Leerink Partners LLC acted as joint book-running managers and Piper
Jaffray & Co. acted as lead manager for the offering.

uniQure is a leader in the field of gene therapy and has developed the first
and currently only gene therapy product to receive regulatory approval in the
European Union. Its first product, Glybera, was approved by the European
Commission in October 2012 under exceptional circumstances for the treatment
of a subset of patients with lipoprotein lipase deficiency, or LPLD, a
potentially life-threatening, orphan metabolic disease. uniQure is developing
a pipeline of additional gene therapies through multiple collaborations that
are designed to accelerate the development and commercialization of these
programs. Forbion invested in uniQure in April 2012 after helping to establish
the company in order to continue the activities of Amsterdam Molecular
Therapeutics (AMT) Holding N.V.

The uniQure investment story exemplifies Forbion’s long-term approach to
building the platform technologies of the future, based on identifying
potential medical break-throughs at an early stage. Forbion has also been
heavily involved at the management level; over time, Forbion’s Managing
Partner Sander van Deventer has been a co-founder, interim-CEO and board
member of uniQure, while Sander Slootweg, Managing Partner at Forbion, has
been its Chairman and non-executive board member. Philip Astley-Sparke, former
CEO and President of Biovex Group, Inc. and a Forbion Venture Partner, is
currently President US at uniQure. This level of hands-on involvement is
typical of how Forbion actively works with its companies to facilitate their
growth and success.

Examples of other exits by Forbion portfolio companies include:

  *Circulite. Inc. to Heartware (HTWR) - Forbion were founders of the company
    and lead investor since 2004 as well as most significant investor at the
    time of exit,
  *Biovex to Amgen - exit value of up to USD 1 billion. Forbion was the
    largest investor as well as lead investor since 2005
  *PanGenetics to Abbott - Forbion was lead investor of its series B
    financing round
  *Fovea Pharmaceuticals to Sanofi - Forbion was lead investor of this
    company’s series B financing round as well.

Recent Forbion portfolio successes also include the listing of bluebird bio,
Inc. (BLUE) in the summer of 2013, the reverse merger of Transave with Insmed,
Inc (INSM) and the substantial regional rights deal of Xention with Servier
closed last year.

These exits show the maturity of Forbion as a firm and of its portfolio. Since
inception, Forbion has launched two main funds, two Co-Investment funds, and
two JV funds with BioGeneration Ventures. As a result, Forbion currently
manages well over EUR 450 million in assets. Most recently, Forbion has
announced raising a new main fund, Forbion Capital Fund III, which targets
investments in drug-, device- and diagnostics companies that develop
tomorrow’s technologies and products that will greatly improve the quality of
patients’ lives.

A registration statement relating to the ordinary shares of uniQure was
declared effective by the Securities and Exchange Commission on February 4,
2014. The uniQure offering was made only by means of a prospectus, copies of
which may be obtained from Jefferies LLC, Attention: Equity Syndicate
Prospectus Department, 520 Madison Avenue, 12th Floor, New York, NY 10022, or
by email at, or by phone at 877-547-6340;
or from Leerink Partners LLC, Attention: Syndicate Department, One Federal
Street, 37th Floor, Boston, MA 02110, or by email at, or
by phone at 800-808-7525.

This press release shall not constitute an offer to sell or a solicitation of
an offer to buy, nor shall there be any sale of, any securities in any state
or jurisdiction in which such offer, solicitation or sale would be unlawful
prior to registration or qualification under the securities laws of any such
state or jurisdiction.


About Forbion Capital Partners

Forbion Capital Partners is a dedicated Life Sciences venture capital firm
with offices in Naarden, The Netherlands, and Munich, Germany. Forbion invests
in life sciences companies in drug discovery & development as well as medical
device companies addressing substantial unmet medical needs. Forbion’s
investment team of nine investment professionals has built an impressive
performance track record since the late nineties with successful investments
in Rhein Biotech, Crucell, Neutec, Glycart, Borean, Impella, Alantos, Acorda,
Fovea, PanGenetics, Argenta Discovery and most recently Biovex and Pathway
Medical. Current assets under management exceed $550m, split between four
active funds and comprising some 29 promising portfolio companies. Forbion
Capital Partners Fund II is supported by the European Investment Fund through
its ERP and LfA facilities. Forbion co-manages Biogeneration Ventures, an
early stage fund focused on (academic) spin-outs and seed investments in the
Netherlands. For more information, please visit


For further information please contact
Sander Slootweg
Forbion Capital Partners
Instinctif Partners (on behalf of Forbion)
Melanie Toyne Sewell / Robert Mayer / Cora Kaiser
Press spacebar to pause and continue. Press esc to stop.